The company has not filed an annual or quarterly report since its Q3 FY2021 10-Q, filed Nov 12, 2021. Its latest SEC filing is a 15-12B from Dec 28, 2021.
10-Q for Q3 FY2021, filed Nov 12, 2021
The sections below describe the company as of the FY2020 annual report.
Develops an acoustic shockwave medical device for tattoo removal and cellulite treatment for dermatologists, plastic surgeons and physician-supervised medi-spas.
10-K for FY2020, filed Mar 4, 2021We are a medical device company with a novel and proprietary platform technology licensed from MD Anderson. Our Rapid Acoustic Pulse…View ↗
We received clearance for our RAP device for tattoo removal from the U.S. Food and Drug Administration ("FDA") in May 2019 allowing our…View ↗
Our business model anticipates generating revenue from the sale of our RAP console to dermatologists, plastic surgeons, and other physician…View ↗
No revenue was reported.
10-K for FY2020, filed Mar 5, 2021
Plans to sell its acoustic shockwave devices to dermatologists, plastic surgeons and other physician offices, and to medi-spas under a doctor's supervision.
10-K for FY2020, filed Mar 4, 2021
8-K, filed Dec 16, 2021
At the Effective Time, as contemplated by the Merger Agreement, Merger Sub merged with and into the Company, with the Company continuing as…View ↗
8-K, filed May 10, 2021
Pursuant to the Merger Agreement, upon the closing of the Merger (the “Closing”), each outstanding share of Company common stock, other…View ↗
Competes with Endo Pharmaceuticals, Merz Pharma, Cynosure, BTL Aesthetics, Cutera, Lumenis, Candela, and OnLight
10-K for FY2020, filed Mar 4, 2021Endo Pharmaceuticals is launching Qwo® in the first half of 2021. Qwo is a prescription injectible treatment for moderate to severe…View ↗
Loading...
